New depression pill shows promise in early trial
NCT ID NCT06126497
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tested a new drug called ropanicant in 41 adults with moderate to severe major depressive disorder. The main goal was to check safety and side effects, while also measuring how well it improved depression symptoms using a standard rating scale. The trial was open-label, meaning everyone knew they were getting the drug, and it has already been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedar Clinical Research, Inc.
Murray, Utah, 84107, United States
-
CenExel iResearch, LLC
Decatur, Georgia, 30030, United States
-
CenExel iResearch, LLC
Savannah, Georgia, 31405, United States
-
Clinical Innovations, Inc
Bellflower, California, 90706, United States
-
Collaborative Neuroscience Research, LLC
Torrance, California, 90504, United States
-
Eastside Therapeutic Resource, Inc. dba Core Clinical Research
Everett, Washington, 98201, United States
-
Innovative Clinical Research, Inc.
Miami Lakes, Florida, 33016, United States
-
NRC Research Institute
Orange, California, 92868, United States
-
Neuro behavioral Clinical Research, Inc
North Canton, Ohio, 44720, United States
-
Precise Research Centers
Flowood, Mississippi, 39232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ropanicant (also known as SUVN-911)
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe depression.
What could go wrong
This was a small, early-phase trial (41 people) with no placebo group, so results may not be reliable or generalizable. Side effects are possible and long-term benefits are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.